
In comparison to the RECIST 1.1 criteria, use of the mpMRI-based NacBI-RADS system for evaluating response to neoadjuvant chemotherapy (NAC) for breast cancer offered an 8 percent higher sensitivity and over 26 percent higher specificity.
Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will
Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will sponsor research led by Dr. Carston Wagner to develop drug candidates with anti-viral or anti-tumor characteristics. The deal is part of the companys plan to diversify from its core MRI contrast agent market (SCAN 3/18/98).





